New York Comprehensive Thalassemia Center
Found 6 results
Author Title [ Type(Desc)] Year
Filters: Author is Glader, Bertil  [Clear All Filters]
Journal Article
Al-Samkari H, van Beers EJ, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N et al..  2020.  Characterization of the severe phenotype of pyruvate kinase deficiency.. Am J Hematol.
Grace RF, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM et al..  2018.  Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.. Blood. 131(20):2183-2192.
Boscoe AN, Yan Y, Hedgeman E, van Beers EJ, Al-Samkari H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S et al..  2021.  Comorbidities and complications in adults with pyruvate kinase deficiency.. Eur J Haematol. 106(4):484-492.
van Beers EJ, van Straaten S, D Morton H, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA et al..  2019.  Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study.. Haematologica. 104(2):e51-e53.
Chonat S, Eber SW, Holzhauer S, Kollmar N, D Morton H, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M et al..  2021.  Pyruvate kinase deficiency in children.. Pediatr Blood Cancer. 68(9):e29148.
Grace RF, Rose C, D Layton M, Galactéros F, Barcellini W, D Morton H, van Beers EJ, Yaish H, Ravindranath Y, Kuo KHM et al..  2019.  Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.. N Engl J Med. 381(10):933-944.